© 2013

Resistance to Immunotherapeutic Antibodies in Cancer

Strategies to Overcome Resistance

  • Benjamin¬†Bonavida
  • Summarizes common and unique features of mAbs against various cancers

  • Explores the latest developments on the molecular, biochemical and genetic mechanisms of resistance by various mAbs

  • Covers the potential use of the combination treatment of mAbs with other drugs/mAbs to reverse resistance


Part of the Resistance to Targeted Anti-Cancer Therapeutics book series (RTACT, volume 2)

Table of contents

  1. Front Matter
    Pages i-xiii
  2. Yangyang Wang, Francesco Sabbatino, Ling Yu, Elvira Favoino, Xinhui Wang, Matteo Ligorio et al.
    Pages 25-47
  3. Emily L. Williams, Sean H. Lim, Stephen A. Beers, Peter W. Johnson, Jonathan C. Strefford, Martin J. Glennie et al.
    Pages 49-71
  4. Back Matter
    Pages 201-202

About this book


The current application of antibody-meditated targeted therapy against cancer has resulted in significant objective clinical responses, prolongation of survival and even cures. More than 20 mAbs have been approved for human use targeting a range of different cancers. However, a major drawback of mAb therapeutics is that a subset of patients does not initially respond and another initially responding subset develops resistance to further treatments. At the present time, there are no effective therapies for these subsets of cancer patients. The analyses of underlying mechanisms responsible for resistance are necessary to develop and generate new targeted therapies that overcome the resistance.

Resistance to Immunotherapeutic Antibodies in Cancer: Strategies to Overcome Resistance is a timely volume that deals with various mechanisms of resistance to anti-cancer mAbs therapeutics as well as it deals with novel approaches to overcome resistance. The reviews in this volume are written by highly qualified, established and experienced leaders in the field of resistance to anti-cancer mAbs.


Rituximab antibody-drug conjugates cancer drug resistance mABs monoclonal antibody

Editors and affiliations

  • Benjamin¬†Bonavida
    • 1
  1. 1.Molecular GeneticsUniversity of California, Los Angeles Dept. Microbiology, Immunology &Los AngelesUSA

About the editors

Dr. Benjamin Bonavida is a professor at UCLA's David Geffen School of Medicine for the Department of Microbiology, Immunology, & Molecular Genetics. His other appointments include being a member of the Department of Defense Congressionally Directed Medical Research Program, Member of the National Cancer Institute's SPORE Program, member of the International Scientific Advisory Board of the Israel Cancer Research Foundation, to name a few. He's currently a scientific reviewer for several journals and a member of editorial boards including Journal of Clinical Immunology, International Journal of Oncology, and Cancer Biotherapy & Radiopharmaceuticals. In his career, he's published over 450 papers and reviews, and he's also edited two books with Springer in the past. For more information, please see the CV attached herewith.

Bibliographic information

  • Book Title Resistance to Immunotherapeutic Antibodies in Cancer
  • Book Subtitle Strategies to Overcome Resistance
  • Editors Benjamin Bonavida
  • Series Title Resistance to Targeted Anti-Cancer Therapeutics
  • Series Abbreviated Title Resistance to Targeted Anti-Cancer Therapeutics
  • DOI
  • Copyright Information Springer Science+Business Media New York 2013
  • Publisher Name Springer, New York, NY
  • eBook Packages Biomedical and Life Sciences Biomedical and Life Sciences (R0)
  • Hardcover ISBN 978-1-4614-7653-5
  • Softcover ISBN 978-1-4899-8732-7
  • eBook ISBN 978-1-4614-7654-2
  • Series ISSN 2196-5501
  • Series E-ISSN 2196-551X
  • Edition Number 1
  • Number of Pages XIII, 202
  • Number of Illustrations 0 b/w illustrations, 0 illustrations in colour
  • Topics Cancer Research
    Molecular Medicine
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Oncology & Hematology
Consumer Packaged Goods